How much profit has Cellectis made this year?
Cellectis has made -58.76 M USD this year.
Cellectis Net Income 2024
Cellectis Net Income
-58.76 M USD
Ticker
ALCLS.PA
ISIN
FR0010425595
WKN
A0MKPR
In 2024, Cellectis's profit amounted to -58.76 M USD, a -41.86% increase from the -101.06 M USD profit recorded in the previous year.
The Cellectis Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2029e | - |
| 2028e | - |
| 2027e | - |
| 2026e | -742.56 |
| 2025e | -75,277.44 |
| 2024e | -58,755.38 |
| 2023 | -101,059 |
| 2022 | -106,139 |
| 2021 | -114,197 |
| 2020 | -81,074 |
| 2019 | -102,091 |
| 2018 | -78,693 |
| 2017 | -99,368 |
| 2016 | -67,255 |
| 2015 | -22,796 |
| 2014 | 22.04 |
| 2013 | -81,040 |
| 2012 | -28,090 |
| 2011 | -33,150 |
| 2010 | -10,990 |
| 2009 | -10,770 |
| 2008 | 190 |
| 2007 | -4,090 |
| 2006 | -4,260 |
| 2005 | -960 |
| 2004 | -3,230 |
Cellectis Revenue, EBIT, Net Income FR0010425595 · A0MKPR
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Cellectis, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cellectis from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cellectis’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Cellectis. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Cellectis’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Cellectis’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cellectis’s growth potential.
Cellectis Revenue, EBIT and net profit per share
| Date | Cellectis Revenue | Cellectis EBIT | Cellectis Net Income |
|---|---|---|---|
| 2029e | 166.34 M undefined | 0 undefined | 0 undefined |
| 2028e | 121.58 M undefined | -17.54 M undefined | 0 undefined |
| 2027e | 85.88 M undefined | -44.67 M undefined | 0 undefined |
| 2026e | 132.42 M undefined | -3.4 M undefined | -742,564.1 undefined |
| 2025e | 70.56 M undefined | -93.83 M undefined | -75.28 M undefined |
| 2024e | 21.11 M undefined | -94.95 M undefined | -58.76 M undefined |
| 2023 | 9.19 M undefined | -97.3 M undefined | -101.06 M undefined |
| 2022 | 25.73 M undefined | -89.67 M undefined | -106.14 M undefined |
| 2021 | 38.6 M undefined | -103.48 M undefined | -114.2 M undefined |
| 2020 | 59.56 M undefined | -42.31 M undefined | -81.07 M undefined |
| 2019 | 22.99 M undefined | -123.55 M undefined | -102.09 M undefined |
| 2018 | 21.43 M undefined | -105.09 M undefined | -78.69 M undefined |
| 2017 | 33.72 M undefined | -92.65 M undefined | -99.37 M undefined |
| 2016 | 56.44 M undefined | -67.3 M undefined | -67.26 M undefined |
| 2015 | 62.57 M undefined | -30.98 M undefined | -22.8 M undefined |
| 2014 | 23.83 M undefined | -5.78 M undefined | 22,036 undefined |
| 2013 | 10.23 M undefined | -43.42 M undefined | -81.04 M undefined |
| 2012 | 14.52 M undefined | -25.21 M undefined | -28.09 M undefined |
| 2011 | 13.81 M undefined | -27.16 M undefined | -33.15 M undefined |
| 2010 | 10.81 M undefined | -15.32 M undefined | -10.99 M undefined |
| 2009 | 10.59 M undefined | -13.34 M undefined | -10.77 M undefined |
| 2008 | 15.51 M undefined | -5.04 M undefined | 190,000 undefined |
| 2007 | 1.98 M undefined | -7.3 M undefined | -4.09 M undefined |
| 2006 | 1.49 M undefined | -4.67 M undefined | -4.26 M undefined |
| 2005 | 7.34 M undefined | -1.55 M undefined | -960,000 undefined |
| 2004 | 870,000 undefined | -4.2 M undefined | -3.23 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 870,000 USD | -4.2 M USD | -3.23 M USD |
| 2005 | 7.34 M USD | -1.55 M USD | -960,000 USD |
| 2006 | 1.49 M USD | -4.67 M USD | -4.26 M USD |
| 2007 | 1.98 M USD | -7.3 M USD | -4.09 M USD |
| 2008 | 15.51 M USD | -5.04 M USD | 190,000 USD |
| 2009 | 10.59 M USD | -13.34 M USD | -10.77 M USD |
| 2010 | 10.81 M USD | -15.32 M USD | -10.99 M USD |
| 2011 | 13.81 M USD | -27.16 M USD | -33.15 M USD |
| 2012 | 14.52 M USD | -25.21 M USD | -28.09 M USD |
| 2013 | 10.23 M USD | -43.42 M USD | -81.04 M USD |
| 2014 | 23.83 M USD | -5.78 M USD | 22,036 USD |
| 2015 | 62.57 M USD | -30.98 M USD | -22.8 M USD |
| 2016 | 56.44 M USD | -67.3 M USD | -67.26 M USD |
| 2017 | 33.72 M USD | -92.65 M USD | -99.37 M USD |
| 2018 | 21.43 M USD | -105.09 M USD | -78.69 M USD |
| 2019 | 22.99 M USD | -123.55 M USD | -102.09 M USD |
| 2020 | 59.56 M USD | -42.31 M USD | -81.07 M USD |
| 2021 | 38.6 M USD | -103.48 M USD | -114.2 M USD |
| 2022 | 25.73 M USD | -89.67 M USD | -106.14 M USD |
| 2023 | 9.19 M USD | -97.3 M USD | -101.06 M USD |
| 2024e | 21.11 M USD | -94.95 M USD | -58.76 M USD |
| 2025e | 70.56 M USD | -93.83 M USD | -75.28 M USD |
| 2026e | 132.42 M USD | -3.4 M USD | -742,564.1 USD |
| 2027e | 85.88 M USD | -44.67 M USD | 0 USD |
| 2028e | 121.58 M USD | -17.54 M USD | 0 USD |
| 2029e | 166.34 M USD | 0 USD | 0 USD |
Cellectis stock margins FR0010425595 · A0MKPR
The Cellectis margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cellectis. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cellectis.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Cellectis's sales revenue. A higher gross margin percentage indicates that the Cellectis retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Cellectis's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Cellectis's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cellectis's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cellectis. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cellectis's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Cellectis Margin History
| Cellectis Gross margin | Cellectis Profit margin | Cellectis EBIT margin | Cellectis Profit margin |
|---|---|---|---|
| 2029e | -331.61 % | 0 % | 0 % |
| 2028e | -331.61 % | -14.43 % | 0 % |
| 2027e | -331.61 % | -52.02 % | 0 % |
| 2026e | -331.61 % | -2.57 % | -0.56 % |
| 2025e | -331.61 % | -132.97 % | -106.69 % |
| 2024e | -331.61 % | -449.8 % | -278.33 % |
| 2023 | -331.61 % | -1,058.44 % | -1,099.3 % |
| 2022 | -72.78 % | -348.56 % | -412.59 % |
| 2021 | -71.15 % | -268.11 % | -295.87 % |
| 2020 | 22.63 % | -71.03 % | -136.11 % |
| 2019 | -163.95 % | -537.42 % | -444.07 % |
| 2018 | -155.27 % | -490.35 % | -367.18 % |
| 2017 | -41.17 % | -274.8 % | -294.73 % |
| 2016 | 35.2 % | -119.24 % | -119.15 % |
| 2015 | 62.14 % | -49.52 % | -36.44 % |
| 2014 | 60.99 % | -24.25 % | 0.09 % |
| 2013 | -78.49 % | -424.44 % | -792.18 % |
| 2012 | -22.11 % | -173.62 % | -193.46 % |
| 2011 | -78.78 % | -196.67 % | -240.04 % |
| 2010 | -41.54 % | -141.72 % | -101.67 % |
| 2009 | -58.26 % | -125.97 % | -101.7 % |
| 2008 | 89.56 % | -32.5 % | 1.23 % |
| 2007 | 30.3 % | -368.69 % | -206.57 % |
| 2006 | -146.98 % | -313.42 % | -285.91 % |
| 2005 | 62.13 % | -21.12 % | -13.08 % |
| 2004 | -132.18 % | -482.76 % | -371.26 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | -132.18 % | -482.76 % | -371.26 % |
| 2005 | 62.13 % | -21.12 % | -13.08 % |
| 2006 | -146.98 % | -313.42 % | -285.91 % |
| 2007 | 30.3 % | -368.69 % | -206.57 % |
| 2008 | 89.56 % | -32.5 % | 1.23 % |
| 2009 | -58.26 % | -125.97 % | -101.7 % |
| 2010 | -41.54 % | -141.72 % | -101.67 % |
| 2011 | -78.78 % | -196.67 % | -240.04 % |
| 2012 | -22.11 % | -173.62 % | -193.46 % |
| 2013 | -78.49 % | -424.44 % | -792.18 % |
| 2014 | 60.99 % | -24.25 % | 0.09 % |
| 2015 | 62.14 % | -49.52 % | -36.44 % |
| 2016 | 35.2 % | -119.24 % | -119.15 % |
| 2017 | -41.17 % | -274.8 % | -294.73 % |
| 2018 | -155.27 % | -490.35 % | -367.18 % |
| 2019 | -163.95 % | -537.42 % | -444.07 % |
| 2020 | 22.63 % | -71.03 % | -136.11 % |
| 2021 | -71.15 % | -268.11 % | -295.87 % |
| 2022 | -72.78 % | -348.56 % | -412.59 % |
| 2023 | -331.61 % | -1,058.44 % | -1,099.3 % |
| 2024e | -331.61 % | -449.8 % | -278.33 % |
| 2025e | -331.61 % | -132.97 % | -106.69 % |
| 2026e | -331.61 % | -2.57 % | -0.56 % |
| 2027e | -331.61 % | -52.02 % | 0 % |
| 2028e | -331.61 % | -14.43 % | 0 % |
| 2029e | -331.61 % | 0 % | 0 % |
Cellectis Aktienanalyse
What does Cellectis do?
Cellectis SA is an emerging biotechnology company focused on developing innovative therapies for cancer and other serious diseases. It was founded in 1999 by a French scientist named André Choulika and is headquartered in Paris, France. Cellectis' main business is the development of CAR-T cell therapies, which involve reprogramming immune cells to target specific types of cancer. This method specifically targets cancer cells while leaving healthy cells unaffected, offering a more precise and less invasive alternative to traditional cancer treatments. Cellectis' business model is centered around developing tailored cancer treatments for individual patients using its Cellectis System, a combination of genomic and cellular technologies. The company also has subsidiaries and joint ventures focusing on different segments of the biopharmaceutical market, such as Calyxt, which specializes in genetic modification of crops, and Ectycell, which focuses on developing cell therapies for rare blood diseases. Cellectis offers a range of products and services focused on cancer drug development, including cell therapies, genetic testing, clinical trials, and consulting services. Its products and services are tailored to the individual needs of patients and aim to revolutionize cancer treatment through advanced technology and innovative approaches. In summary, Cellectis is an innovative biotechnology company successfully focusing on developing tailored cancer therapies. With its wide range of products and services catering to patient needs, and with advancements in cancer therapy, Cellectis is well positioned to become a key player in the biopharmaceutical industry. Cellectis ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Cellectis's Profit Margins
The profit margins of Cellectis represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Cellectis's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Cellectis's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Cellectis's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Cellectis’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Cellectis stock
How has the profit developed compared to last year?
The profit has increased by -41.86% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Cellectis publish its earnings?
Cellectis publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Cellectis?
The profits of Cellectis are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Cellectis?
You can learn more about the earnings of Cellectis by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Cellectis pay?
Over the past 12 months, Cellectis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cellectis is expected to pay a dividend of 0 USD.
What is the dividend yield of Cellectis?
The current dividend yield of Cellectis is .
When does Cellectis pay dividends?
Cellectis pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Cellectis?
Cellectis paid dividends every year for the past 0 years.
What is the dividend of Cellectis?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Cellectis located?
Cellectis is assigned to the 'Health' sector.
Wann musste ich die Aktien von Cellectis kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Cellectis from 7/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/30/2024.
When did Cellectis pay the last dividend?
The last dividend was paid out on 7/30/2024.
What was the dividend of Cellectis in the year 2023?
In the year 2023, Cellectis distributed 0 USD as dividends.
In which currency does Cellectis pay out the dividend?
The dividends of Cellectis are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Cellectis stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Cellectis
Our stock analysis for Cellectis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cellectis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
